Quick Answer
REGENEREX PHARMA, INC. reported Cash and Equivalents of $653.0 thousand for fiscal year 2025.
REGENEREX PHARMA, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $653.0K | +175444.4% |
| 2024 | $372.00 | -67.2% |
| 2023 | $1.1K | -57.0% |
| 2022 | $2.6K | -61.8% |
| 2021 | $6.9K | +26.4% |
| 2020 | $5.5K | -93.8% |
| 2019 | $88.5K | +5024.2% |
| 2018 | $1.7K | +31.0% |
| 2014 | $1.3K | +740.1% |
| 2013 | $157.00 | -98.0% |
| 2012 | $7.8K | +369.8% |
| 2011 | $1.7K | -63.5% |
| 2010 | $4.5K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.7K | +3865.6% | -93.2% |
| June 30, 2025 | $172.4K | — | -73.6% |
| March 31, 2025 | $653.0K | +175444.4% | +193102.7% |
| December 31, 2024 | $338.00 | -95.7% | +15.0% |
| September 30, 2024 | $294.00 | -95.2% | -21.0% |
| March 31, 2024 | $372.00 | -67.2% | -95.3% |
| December 31, 2023 | $7.9K | +553.0% | +29.2% |
| September 30, 2023 | $6.1K | +866.6% | -91.0% |
- REGENEREX PHARMA, INC. showed an increase of +175444.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, REGENEREX PHARMA, INC.’s cash and equivalents has grown by 14296.5% (from $4.5 thousand to $653.0 thousand).
- The most recent figure is from REGENEREX PHARMA, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: